Standout Papers

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): ... 2016 2026 2019 2022 344
  1. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials (2016)
    Nicola A. Hanania, Phillip E. Korenblat et al. The Lancet Respiratory Medicine

Immediate Impact

5 from Science/Nature 60 standout
Sub-graph 1 of 20

Citing Papers

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
2024 Standout
Interstitial Lung Disease
2024 Standout
1 intermediate paper

Works of Julie Olsson being referenced

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
2020
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
2015

Author Peers

Author Last Decade Papers Cites
Julie Olsson 582 576 178 281 13 1.1k
May Mo 486 810 173 369 20 1.3k
Paul Stryszak 453 587 170 341 20 1.3k
Patricia Rohane 256 424 42 355 10 955
Richárd Márkus 264 261 318 409 29 1.1k
Angela Morgan 601 921 67 428 10 1.1k
Michael C. Nivens 351 395 101 230 24 854
Necdet B. Gunsoy 634 819 100 207 29 1.0k
Dana McClintock 361 332 28 205 12 850
Edward Piper 385 665 15 317 8 851
Tuyet‐Hang Pham 296 418 42 514 19 1.1k

All Works

Loading papers...

Rankless by CCL
2026